drugset
drugset / Trial / NCT07288203

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

NCT07288203 ↗

Phase 2 Active not recruiting 24 enrolled Iovance Biotherapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma

Timeline

Start
2025-11-28
Primary completion
2027-12
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tumor Infiltrating Lymphocytes Cell therapy — Other

Indications

cutaneous melanoma